(RTTNews) - Illumina, Inc. (ILMN), a biotechnology company specializing in DNA sequencing and array-based technologies, on Monday announced that it has been selected to provide whole-genome sequencing services for Singapore's SG-INSIGHT study, part of Phase III of the country's N

Illumina Expands Singapore Precision Medicine Partnership With SG-INSIGHT Study; Stock Up 

The average one-year price target for Illumina (NASDAQGS:ILMN) (SWX:ILMN) has been revised to $250.77 / share. This is an increase of 19.65% from the prior estimate of $209.59 dated September 29, 2026. These figures represent aggregate analyst targets compiled from various resear

Illumina Consensus Price Target Increased by 19.65% to $250.77

(RTTNews) - Illumina, Inc. (ILMN), a provider of genetic and genomic analysis technologies, has launched the Illumina BioInsight Platform, a unified software environment designed to help researchers generate biological insights from genomic and multiomic data.
 
The platform brin

Illumina Launches BioInsight Platform For Genomic And Multiomic Research 

(RTTNews) - The following biotech stocks reached a 52-week high on October 5, 2026, driven by key catalysts such as encouraging clinical research data.

Biotech Stocks At 52-Week Highs - PCVX +31% On Phase 3 Results, INFU, ILMN +7%, CRL+7%, HTFL +5% 

Illumina (NASDAQ: ILMN) is building a deeper AI strategy around the biological data created by its sequencing technology. The Billion Cell Atlas, expanding drugmaker partnerships, and improving core business could create a new growth engine if Illumina can turn its scientific adv

Where Will Illumina Stock Be in 5 Years If Its AI Bet Pays Off?

REGN vs. ILMN: Which Stock Is the Better Value Option?

REGN or ILMN: Which Is the Better Value Stock Right Now?

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Illumina, Inc. News